Infoway announced an increase in interest in the Pre-IPO of the Swiss holding Si14 AG after the presentation of the holding’s medical projects at the BRICS and BRICS+ International Summit in Dubai. The investment attractiveness of Si14 AG shares is growing after the holding introduced patented colloidal nanotechnologies in the pharmaceuticalindustry, according to Infoway Marketing, the official representative of Si14 AGInfoway Marketing.
Analysts and investors are showing increased interest in the Pre-IPO of the Swiss holding Si14 AG. The company is engaged in the implementation of colloidal technologies in the field of medicine in the BRICS countries. The drugs are based on nanoparticles of magnesium, zinc, copper and silver, which can effectively counteract infections. They have become an alternative to antibiotics, especially in developing countries. Technologies are implemented through the Si14 Pharma direction. The founder of the Swiss holding company Si14 AG is Viktor Kopylov.
